Alkermes (ALKS) Competitors $29.36 +0.16 (+0.55%) Closing price 04:00 PM EasternExtended Trading$29.37 +0.01 (+0.03%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ALKS vs. ABEO, MEDP, OMCL, AMN, BIIB, UTHR, INCY, NBIX, EXEL, and BMRNShould you be buying Alkermes stock or one of its competitors? The main competitors of Alkermes include Abeona Therapeutics (ABEO), Medpace (MEDP), Omnicell (OMCL), AMN Healthcare Services (AMN), Biogen (BIIB), United Therapeutics (UTHR), Incyte (INCY), Neurocrine Biosciences (NBIX), Exelixis (EXEL), and BioMarin Pharmaceutical (BMRN). These companies are all part of the "medical" sector. Alkermes vs. Its Competitors Abeona Therapeutics Medpace Omnicell AMN Healthcare Services Biogen United Therapeutics Incyte Neurocrine Biosciences Exelixis BioMarin Pharmaceutical Abeona Therapeutics (NASDAQ:ABEO) and Alkermes (NASDAQ:ALKS) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk, media sentiment and dividends. Which has more volatility & risk, ABEO or ALKS? Abeona Therapeutics has a beta of 1.51, indicating that its share price is 51% more volatile than the S&P 500. Comparatively, Alkermes has a beta of 0.44, indicating that its share price is 56% less volatile than the S&P 500. Do insiders & institutionals believe in ABEO or ALKS? 80.6% of Abeona Therapeutics shares are owned by institutional investors. Comparatively, 95.2% of Alkermes shares are owned by institutional investors. 6.9% of Abeona Therapeutics shares are owned by insiders. Comparatively, 4.4% of Alkermes shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has preferable earnings and valuation, ABEO or ALKS? Alkermes has higher revenue and earnings than Abeona Therapeutics. Abeona Therapeutics is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAbeona Therapeutics$3.50M96.91-$63.73M-$1.27-5.22Alkermes$1.51B3.20$367.07M$2.0914.05 Is ABEO or ALKS more profitable? Alkermes has a net margin of 23.30% compared to Abeona Therapeutics' net margin of 0.00%. Alkermes' return on equity of 27.52% beat Abeona Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Abeona TherapeuticsN/A -118.82% -52.48% Alkermes 23.30%27.52%17.98% Do analysts recommend ABEO or ALKS? Abeona Therapeutics presently has a consensus target price of $19.25, indicating a potential upside of 190.35%. Alkermes has a consensus target price of $40.92, indicating a potential upside of 39.36%. Given Abeona Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Abeona Therapeutics is more favorable than Alkermes.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Abeona Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Alkermes 0 Sell rating(s) 3 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.83 Does the media favor ABEO or ALKS? In the previous week, Abeona Therapeutics had 9 more articles in the media than Alkermes. MarketBeat recorded 22 mentions for Abeona Therapeutics and 13 mentions for Alkermes. Alkermes' average media sentiment score of 0.86 beat Abeona Therapeutics' score of 0.20 indicating that Alkermes is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abeona Therapeutics 7 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Alkermes 5 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryAlkermes beats Abeona Therapeutics on 11 of the 17 factors compared between the two stocks. Get Alkermes News Delivered to You Automatically Sign up to receive the latest news and ratings for ALKS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALKS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALKS vs. The Competition Export to ExcelMetricAlkermesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.84B$2.93B$5.50B$9.39BDividend YieldN/A2.46%4.25%4.09%P/E Ratio14.0520.3128.1019.86Price / Sales3.20261.57402.2879.25Price / Cash10.8842.3835.5357.53Price / Book3.247.838.265.72Net Income$367.07M-$55.11M$3.24B$257.80M7 Day Performance-3.61%2.18%0.50%1.06%1 Month Performance-1.38%12.98%7.99%11.30%1 Year Performance19.30%1.98%28.68%17.00% Alkermes Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALKSAlkermes4.7987 of 5 stars$29.36+0.5%$40.92+39.4%+18.7%$4.84B$1.51B14.051,800Analyst ForecastABEOAbeona Therapeutics3.7436 of 5 stars$5.75-2.4%$19.25+234.8%+17.2%$294.17M$3.50M-4.5390Analyst ForecastMEDPMedpace3.756 of 5 stars$318.90-0.8%$344.82+8.1%-31.2%$9.17B$2.11B24.345,900Upcoming EarningsOMCLOmnicell3.4149 of 5 stars$28.92-3.1%$44.83+55.0%+0.8%$1.35B$1.11B62.873,670News CoverageAnalyst RevisionAMNAMN Healthcare Services4.3681 of 5 stars$21.23-3.1%$32.08+51.1%-65.0%$812.68M$2.98B-4.902,968Analyst RevisionBIIBBiogen4.9034 of 5 stars$130.13-2.1%$188.48+44.8%-42.9%$19.07B$9.68B12.857,605Trending NewsInsider TradeAnalyst RevisionUTHRUnited Therapeutics4.9873 of 5 stars$290.39-1.4%$386.15+33.0%-9.2%$13.10B$2.88B11.591,305Positive NewsInsider TradeINCYIncyte4.622 of 5 stars$67.27-1.7%$74.53+10.8%+8.2%$13.02B$4.24B210.232,617Trending NewsAnalyst ForecastInsider TradeAnalyst RevisionNBIXNeurocrine Biosciences4.4941 of 5 stars$127.88-1.0%$162.00+26.7%-9.5%$12.66B$2.36B43.351,800Trending NewsAnalyst RevisionEXELExelixis4.7739 of 5 stars$44.16-4.3%$43.56-1.4%+96.9%$12.04B$2.17B20.071,147Analyst ForecastBMRNBioMarin Pharmaceutical4.9888 of 5 stars$57.41-0.2%$93.61+63.1%-32.0%$11.01B$2.85B21.343,040News CoverageAnalyst Forecast Related Companies and Tools Related Companies Abeona Therapeutics Alternatives Medpace Alternatives Omnicell Alternatives AMN Healthcare Services Alternatives Biogen Alternatives United Therapeutics Alternatives Incyte Alternatives Neurocrine Biosciences Alternatives Exelixis Alternatives BioMarin Pharmaceutical Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALKS) was last updated on 7/17/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alkermes plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Alkermes With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
